{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-065959","form_type":"8-K/A","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2026-05-26T10:43:50+00:00","discovered_at":"2026-05-26T10:45:00.320300+00:00","generated_at":"2026-05-26T10:45:05.007062+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity","bullets":["Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.","Company has 45 days (until July 3, 2026) to submit a plan to regain compliance.","Plan hinges on stockholder approval to convert Series A Preferred Stock into common equity.","If plan is rejected or compliance not regained within extension, Nasdaq may delist RNAZ.","Failure to obtain approval by Dec 31, 2026 could trigger redemption of Series A Preferred at fair value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065959","json":"https://secwatch.observer/filing/0001104659-26-065959.json","markdown":"https://secwatch.observer/filing/0001104659-26-065959.md","text":"https://secwatch.observer/filing/0001104659-26-065959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/0001104659-26-065959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/tm2615597d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T10:45:05.007062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}